CGM Subsidy Initiative – AMSL Diabetes


CGM Subsidy Initiative

The Continuous Glucose Monitoring (CGM) Subsidy Initiative has been extended!

As of the 1st March 2020, the Australian Government simplified the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative. This  now allows people with type 1 diabetes under the age of 21 and those over the age of 21 who have valid concessional status to access fully subsidised CGM devices through the National Diabetes Services Scheme (NDSS).

 

Eligibility Criteria:

A summary of the new access from the 1st of March 2020 is:

  • Children and young people under 21 years with type 1 diabetes
  • Children and young people under 21 years with conditions very similar to type 1 diabetes who require insulin, such as cystic fibrosis-related diabetes and neonatal diabetes
  • People with type 1 diabetes aged 21 years or older who have valid concessional status

The eligibility criteria for each group is available on the NDSS. Talk to your healthcare professional to further discuss the eligibility criteria.

What are the steps to access Dexcom CGM through the NDSS Subsidy Initiative (if you have been confirmed eligible)?

  • A healthcare professional will be able to assess your eligibility for the Subsidy Initiative and you will then need to complete the CGM NDSS Order Form available here (Temporary update: To make things easier during COVID-19 pandemic, only your healthcare professional needs to complete the form and you will not be required to co-sign)
  • Once you complete the form, NDSS will be able to confirm your eligibility
  • Once the NDSS confirms eligibility, you will then be sent information on ordering your Dexcom CGM system through your local NDSS Pharmacy/Access Point

Both Dexcom G5 Mobile and Dexcom G4 PLATINUM CGM systems are available to eligible patients who meet the above criteria.

Find more information about continuous glucose monitoring here. 

Learn more about our Dexcom CGM products:

By using a CGM platform, such as Dexcom G5 Mobile or Dexcom G4 PLATINUM studies indicate significantly improved HbA1c1 and lessened risk of hypoglycaemia. 1,2

Both platforms transmit data to display a dynamic trend line which can indicate glucose direction and rate of change. By using CGM, one can proactively manage glucose levels and can treat before hypoglycaemia.

AMSL distribute both Dexcom G5 Mobile and Dexcom G4 PLATINUM systems, which are available for subsidised access. Refer to the table below to compare the differences between both CGM systems available

Always read the label and use only as directed. Read the warnings available on www.amsldiabetes.com.au/resources before purchasing. Consult your healthcare professional to see which product is right for you.

References
1. Šoupal J, Petruželková L, Flekač M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538. doi:10.1089/dia.2016.0171 2. Welsh J, Gao P, Derdzinski M et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther. 2019;21(3):128-132. doi:10.1089/dia.2018.0374
Dexcom, Dexcom G5, Dexcom G4, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

Stay informed with AMSL Diabetes

Now you can get all the latest news and updates of our products, events and resources right into your inbox.

Something went wrong. Please try again later!

Send AMSL Diabetes a message

We are always happy to help, send us a message or enquiry

Shopping cart

Subtotal
Shipping and discount codes are added at checkout.
Checkout
Back to top